Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.
William Kevin KellyDaniel Costin DanilaChia-Chi LinJae Lyun LeeNobuaki MatsubaraPatrick J WardAndrew J ArmstrongDavid W PookMiso KimTanya Barauskas DorffStefanie FischerYung-Chang LinLisa G HorvathChristopher SumeyZhao YangGabor JuridaKristen M SmithJamie N ConnarnHweixian Leong PennyJulia StieglmaierLeonard J ApplemanPublished in: Cancer discovery (2023)
Xaluritamig demonstrated encouraging responses (PSA and RECIST) compared with historical established treatments for patients with late-line mCRPC. This study provides proof of concept for T-cell engagers as a potential treatment for prostate cancer, validates STEAP1 as a target, and supports further clinical investigation of xaluritamig in prostate cancer.